Laminate Medical Technologies appears in FDA device records as the applicant for VasQ, described in the De Novo classification request as a permanent implant surgically placed outside and/or around an artery and/or vein to provide external support to arteriovenous fistulas created for vascular access. The same filing names Laminate Medical Technologies Ltd. as sponsor and establishes the regulation number, class and product code that later submissions reference. The company's own published site describes VasQ as an extravascular support device intended to reinforce the anastomosis, and its publications page lists clinical literature on the device. [4][6][9]
Regulatory identity and classification
The De Novo classification order for DEN220026, dated September 26, 2023, identifies VasQ as an extravascular support for an arteriovenous fistula for vascular access, assigns regulation number 21 CFR 870.4600, Class II, and product code QVQ, and states that the request is granted with special controls. The De Novo request document repeats the same generic device type and describes the implant as placed outside and/or around an artery and/or vein. FDA correspondence is addressed to Orit Yarden, VP Clinical and Regulatory Affairs, at a Tel Aviv address; that address is a filing contact location, not a verified headquarters. [4][8]
Clearance history in the supplied filings
The MedtechLedger collection contains one linked 510(k) record, K263598 for VasQ, with a decision date of October 29, 2026, decision code SESE and decision description Substantially Equivalent; the collection's decision counts show one SESE decision in the collection and one in the record sample. The FDA clearance letter for K263598 states the device is substantially equivalent to its predicate devices and lists the same regulation, class and product code. An earlier clearance letter, K240119 dated February 16, 2024, covers a modified VasQ and reports that the modification involved a braiding contractor change, with verification tests including biocompatibility, device integrity, kink, crush and corrosion. [1][2][7]
Documented device scope
Across the FDA records, VasQ is consistently described as an extravascular support for an arteriovenous fistula for vascular access under 21 CFR 870.4600, Class II, product code QVQ. The K240119 letter frames the modified device as having the same intended use and similar indications, principles of operation and technological characteristics as the predicate VasQ. Laminate's own site describes VasQ as permanent reinforcement at the anastomosis, and its manuals and publications page lists product and patient brochures for US and non-US markets alongside instructions for use and published studies. [2][6][7][9]
Published material and open items
Laminate's publications page lists peer-reviewed articles on VasQ, including a randomized controlled trial in the American Journal of Kidney Diseases and pilot and forearm fistula studies in the Journal of Vascular Access. The company site also references conference presentations from 2018. Ownership, parent entities, headquarters, customers and commercial availability are not established by the numbered sources and remain unknown. [5][9]
